AnaptysBio - AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
ANB032
Rosnilimab
ANB033
ANB101
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Home
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update